- Methodology article
- Open Access
Quantification of PRL/Stat5 signaling with a novel pGL4-CISH reporter
© Fang et al; licensee BioMed Central Ltd. 2008
- Received: 11 October 2007
- Accepted: 06 February 2008
- Published: 06 February 2008
Elevations of serum prolactin (PRL) are associated with an increased risk for breast cancer. PRL signaling through its prolactin receptor (PRLr) involves the Jak2/Stat5 pathway. Luciferase-based reporter assays have been widely used to evaluate the activity of this pathway. However, the existing reporters are often not sensitive enough to monitor the effect of PRL in this pathway.
In this study, a new biologically relevant reporter, pGL4-CISH, was generated to study the PRL/Jak2/Stat5 signaling pathway. The sensitivity of pGL4-CISH to detect PRL was superior to that of several other commonly utilized Stat5-responsive reporters. Interestingly, the enhanced function pGL4-CISH was restricted to the estrogen receptor positive (ER+) human breast cancer cell lines T47D and MCF7, but not in the ER-MDA-231, BT-474, or MCF10A cell lines. Overexpression of Stat5 further enhanced the effect of PRL on pGL4-CISH.
These studies demonstrate that pGL4-CISH is a novel and sensitive reporter for assessing the activity of the PRL/Stat5 signaling pathway in the ER+ human breast cancer cells.
- Reporter Construct
- T47D Cell
- Stat5 Binding Site
- Breast Cancer Cell Line T47D
- PRLr Expression
Prolactin (PRL) is a 22 kDa hormone that stimulates the growth and differentiation of mammary epithelium, and initiates and maintains lactation [1–3]. PRL serum levels range from 5–20 ng/ml in blood in non-pregnant humans and up to 200 ng/ml in pregnant females. The lactogenic actions of PRL are mediated by binding to its receptor (PRLr), an event that activates several proximal PRLr signaling cascades including Jak2-Stat5 [4–8]. PRL-induced autophosphorylation of Jak2 results in the activation of this tyrosine kinase, and its subsequent phosphorylation of both the PRLr and the PRLr-associated, latent transcription factor Stat5. Following phosphorylation, Stat5 is released from the PRLr, self-dimerizes and is translocated into the nucleus [6, 9–11], where it binds to gene promoter sequences containing Stat5-binding elements, resulting in the induction of gene expression such as Cytokine Inducible SH2-containing protein (CISH or CIS), β-casein, c-Myc, and cyclin D1 [9, 12, 13].
The Jak2/Stat5 pathway is negatively regulated by a feedback loop through the suppressors of cytokine signaling [13, 14], a family of related proteins that includes CISH. The induction of CISH gene expression results in the binding of CISH to the phosphorylated PRLr, which in turn prevents the subsequent binding of Stat5 to PRLr, hence attenuating the PRL/Stat5 signaling pathway . Interestingly, while blocking Stat5 activation CISH does not stop continued Jak2 and MAPK activity. This observation, coupled with the detection of elevated expression of CISH protein in primary human breast cancers, has led to the hypothesis that PRL-induced CISH expression may facilitate the pathogenesis of breast cancer by enhancing cell proliferation triggered by Jak2/MAPK activity at the expense of cell differentiation mediated by Stat5 .
Luciferase-reporter assays are widely used to monitor the cellular events related to transduction and gene expression regulated by specific signaling cascades, such as PRL/Jak2/Stat5 pathway. There are several reporter construct used to study Stat5 activity, such as the LHRE-TK-luc , cyclin D1Δ-944 [12, 18, 19], β-casein-344 , and β-casein-2300 . However, in breast cancer cells these existing reporter constructs have proven to be relatively insensitive to the effects of PRL, requiring supra-physiologic concentrations of PRL (>200 ng/ml) to detect reporter induction. To generate a more PRL-sensitive reporter construct, our analysis of the literature suggested that the PRL-responsive CISH promoter could be an optimal candidate as it contains four Stat5 binding sites, and is rapidly activated after PRL stimulation . Cloning of the promoter region of the CISH gene into the improved pGL4.10 luciferase reporter construct resulted in a highly sensitive, PRL-responsive reporter that should be of widespread utility in examining PRL/Stat5 pathway in ER+ human breast cancer cells.
Cell lines, reagents and vectors
The breast cancer cell lines T47D, MCF7, BT-474, MDA-231 and the non-tumorigenic epithelial cell line MCF10A from American Type Culture Collection (ATCC) were maintained in Dulbecco's modified Eagle's medium (DMEM) or the similar growth medium supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (Pen/Strep 50 ug/ml) in a humidified atmosphere of 5% CO2 at 37°C. Human recombinant prolactin was obtained from Dr. Michael Hodsdon (Yale University) . Transfection reagents Fugene HD (Roche, Indianapolis, IN) for MCF7 cells and Lipofactamine 2000 (Invitrogen, Casbad, CA) for all other cell lines were used for transfection. Vectors Renilla luciferase reporter pGL4.73 (Promega), pGL4.10 (Promega), pGL4-CISH (this study, description below), pEF-PRLr , and pEF V5/His A (Invitrogen) were used for transfection.
The CISH promoter region (-1034 to +1) was PCR amplified using the primers olg104 5'CCGCCC CAACCTCTATCA-3' and olg110 5'-GGCCAAGCTTACTGAGAGGCAGTGGCG CGGACCGCC-3' (the bold sequence is a HindIII restriction site) using HiFi PCR kit (Invitrogen). For the vector, a promoter-less pGL4 luciferase expression construct (Promega, Madison, WI) was utilized. The EcoRV and HindIII digested pGL4.10 reporter and the HindIII digested PCR product were ligated and transformed into TOP10 E coli cells. The construct was confirmed by sequencing using primer olg18 (5'-CCGTCTTCGAGTGGGTAGAAT-3') and RVprimer 3 (Promega). The generated reporter was termed pGL4-CISH. The cyclin D1 promoter region was PCR amplified using the olg88 (5'-ATTGGGTACCTAAATCCCGGGGGACCCA CT-3', the bold sequence is a KpnI restriction site) and olg89 (5'-CCGGAAGCTTGGAGGCTC CAGGACTTTGCA-3', the bold sequence is a HindIII restriction site). The KpnI and HindIII digested PCR product and pGL4.10 reporter backbone were ligated and the construct was named as pGL4-CCND300.
Transfection and dual luciferase assay
T47D cells were plated in a 24-well plate and grown at 60% confluency for transfection. For luciferase assays, 50 ng of a given reporter construct, 0.5 ng of renilla (pGL4.73 from Promega) and/or 250 ng of pCMV-wtStat5a per well were used for transfection. After transfection, cells were maintained in 500 ul of growth media overnight, and then arrested in 200 ul of serum-free, phenol red-free DMEM for 24 hours followed by PRL treatment for 24 hours. After treatment, cells were lysed in 120 ul of 1 × passive lysis buffer (PLB buffer from Promega) at room temperature for 15 minutes. For dual luciferase assay, 25 ul of lysate was aliquoted into a 96-well plate and subjected to analysis of firefly luciferase (50 ul of LAR II) and renilla (50 ul of stop and glow buffer). Luminescence was read on Victor3 1420 Multilabel Counter (Perkin Elmer, Waltham, MA). All analyses were performed in duplicate, with each experiments performed at least twice.
Forty microliters of cell lysates from luciferase assay were loaded onto 10% SDS-PAGE gel. Proteins were transferred onto PVDF membrane and western blots were performed using 50% skim milk (1:1 ratio of skim milk and 1 × TBS). Antibodies anti-Stat5a (Zymed, 71–2400, 1:2000 dilution), anti-PRLr (Zymed, 35–9200, 1:2000 dilution) and anti-GAPDH (Zymed, 39–8600, 1:2000 dilution) were used for Western blot analysis. Images were obtained using a Fujifilm LAS-3000 image analyzer.
Comparison of Reporter Responses to PRL in T47D cells
Stat5 binding sites
Sensitivity to PRL
+ + +
CISH is a repressor through a negative feedback mechanism in the Jak2/Stat5 pathway . A web-based software (TFsearch) was used to search for Stat5 binding sites in the CISH promoter region, and found four Stat5 binding sites in the proximal region (Fig. 1A). In order to evaluate the response of the human CISH promoter in the context of the Stat5/Jak2 signaling pathway, a 1034 bp fragment (-1034 to +1) was cloned into upstream of a luciferase reporter gene in the promoterless pGL4.10 reporter, resulting in a novel reporter construct termed as pGL4-CISH. Initial use of this reporter in T47D cells revealed that the construct was highly responsive to PRL.
The versatility and simplicity of the reporter assay is a powerful tool in the fields of biological and pharmaceutical research , and there is an ongoing need for highly responsive reporters . Until recently, older reporter vector backbones had spurious transcription factor binding sites resulting in both inaccurate and false-positive results. For the studies presented here, a new pGL4 reporter with decreased cryptic DNA regulatory elements and transcription factor binding sites was used as a backbone for reporter. We constructed a novel pGL4-CISH reporter based on the pGL4 backbone and the Stat5-response-rich-element CISH promoter. The pGL4-CISH DNA dose curve, PRL dose curve and time course parameters were optimized for this reporter. Our results indicated that this reporter had a high sensitivity to PRL in T47D, less so in MCF7, and little to none in ER- cell lines evaluated. As subsequently shown with MCF7 cells, our data would indicate that both PRLr and Stat5a levels contribute to the responsiveness of the pGL4-CISH reporter.
Cell proliferation, as measured by 3H-thymidine incorporation, is a sensitive and simple way to test PRL action . In the T47D proliferation assay, maximal stimulation (2.2-fold over basal levels, reaching a plateau) was achieved with 100 ng/ml of PRL treatment . In our study, pGL4-CISH reporter demonstrated a 2-fold induction upon 1 ng/ml of PRL treatment, suggesting this reporter was significantly more sensitive than the thymidine-incorporated proliferation assay to detect breast cancer cell responsiveness to PRL stimulation.
The luciferase induction of pGL4-CISH, LHRE-TK-luc, Cyclin D1Δ-944, pGL4-CCND300 and Beta-casein2300 reporters was also compared in T47D cells. Results indicated that pGL4-CISH reporter was the most responsive to PRL treatment in T47D cells. A reporter termed -404CIS-LUC containing about 500 bp of human CISH promoter has also been reported . However, this reporter demonstrated poor PRL-induced expression in COS7 cells . We reason the different response to PRL of reporters is due to the limited proximal promoter regions utilized, the different backbones used for reporter construct, and cells lines used for reporter assay.
PRL activates the latent cytoplasmic Stat5 by tyrosine phosphorylation and dimerization in PRL/Jak2/Stat5 pathway . The intranuclear phospho-Stat5 then activates the Stat5-responsive-gene expression. We observed that in the absence of PRL, overexpression of Stat5a does not stimulate pGL4-CISH luciferase. In the presence of PRL, overexpression of Stat5 greatly enhanced the effect of PRL on pGL4-CISH reporter (Fig 4D). These data indicate that the activation of pGL4-CISH is influenced by the level of available Stat5a following PRL treatment.
The pGL4-CISH reporter has potential applications in the analysis of the PRL/Stat5 pathway, CISH promoter analysis, and biological screening for drug discovery. Indeed, as a novel bioassay for PRL, the pGL4-CISH reporter has a sensitivity approaching that of the venerable rat Nb2 lymphoma cell bioassay for PRL. As a distinct advantage, the PGL4-CISH system now provides a sensitive, species homologous assay for the action of human PRL in human cell lines expressing sufficient levels of PRLr and Stat5. The CISH promoter has four Stat5 binding sites but also include other potential transcriptional binding sites such as Sp1, HSF, c-Myb, and GATA-1. Detailed functional mapping of this promoter to characterize the relative contributions of cis-acting elements will improve our understanding of how PRL signaling triggers the response of the CISH at the transcriptional level.
Given its sensitivity to PRL, the pGL4-CISH reporter should be a useful tool in the screening of small compound libraries in the identification of novel PRL/Stat5 inhibitors.
We thank Alyson Fiorillo and Chevaunne Edwards in the lab for manuscript proofreading. We also thank undergraduate student Diana Gutierrez's technical work on the vector construction of pGL4-CCND300. This work was supported by National Institute of Health (RO1CA-102682), and support from the Avon and Lynn Sage Foundations, and the Zell Scholar's Fund.
- Clevenger CV, Plank TL: Prolactin as an autocrine/paracrine factor in breast tissue. J Mammary Gland Biol Neoplasia. 1997, 2: 59-68. 10.1023/A:1026325630359.View ArticleGoogle Scholar
- Vonderhaar BK: Prolactin involvement in breast cancer. Endocr Relat Cancer. 1999, 6: 389-404. 10.1677/erc.0.0060389.View ArticleGoogle Scholar
- Gadd SL, Clevenger CV: Ligand-independent dimerization of the human prolactin receptor isoforms: functional implications. Mol Endocrinol. 2006, 20: 2734-2746. 10.1210/me.2006-0114.View ArticleGoogle Scholar
- Kirken RA, Malabarba MG, Xu J, Liu X, Farrar WL, Hennighausen L, Larner AC, Grimley PM, Rui H: Prolactin stimulates serine/tyrosine phosphorylation and formation of heterocomplexes of multiple Stat5 isoforms in Nb2 lymphocytes. J Biol Chem. 1997, 272: 14098-14103. 10.1074/jbc.272.22.14098.View ArticleGoogle Scholar
- Ali S, Nouhi Z, Chughtai N: SHP-2 regulates SOCS-1-mediated Janus kinase-2 ubiquitination/degradation downstream of the prolactin receptor. J Biol Chem. 2003, 278: 52021-52031. 10.1074/jbc.M306758200.View ArticleGoogle Scholar
- Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G, Ihle JN: Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998, 93: 385-395. 10.1016/S0092-8674(00)81167-8.View ArticleGoogle Scholar
- Miller SL, Antico G, Raghunath PN, Tomaszewski JE, Clevenger CV: Nek3 kinase regulates prolactin-mediated cytoskeletal reorganization and motility of breast cancer cells. Oncogene. 2007, 26: 4668-4678. 10.1038/sj.onc.1210264.View ArticleGoogle Scholar
- Li Y, Kumar KG, Tang W, Spiegelman VS, Fuchs SY: Negative regulation of prolactin receptor stability and signaling mediated by SCF(beta-TrCP) E3 ubiquitin ligase. Mol Cell Biol. 2004, 24: 4038-4048. 10.1128/MCB.24.9.4038-4048.2004.View ArticleGoogle Scholar
- Clevenger CV, Furth PA, Hankinson SE, Schuler LA: The role of prolactin in mammary carcinoma. Endocr Rev. 2003, 24: 1-27. 10.1210/er.2001-0036.View ArticleGoogle Scholar
- Chilton BS, Hewetson A: Prolactin and growth hormone signaling. Curr Top Dev Biol. 2005, 68: 1-23. 10.1016/S0070-2153(05)68001-5.View ArticleGoogle Scholar
- Huang Y, Li X, Jiang J, Frank SJ: Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells. Oncogene. 2006, 25: 7565-7576. 10.1038/sj.onc.1209740.View ArticleGoogle Scholar
- Brockman JL, Schroeder MD, Schuler LA: PRL activates the cyclin D1 promoter via the Jak2/Stat pathway. Mol Endocrinol. 2002, 16: 774-784. 10.1210/me.16.4.774.View ArticleGoogle Scholar
- Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, Miyajima A, Yoshimura A: CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood. 1997, 89: 3148-3154.Google Scholar
- Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE: Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene. 2006Google Scholar
- Dif F, Saunier E, Demeneix B, Kelly PA, Edery M: Cytokine-inducible SH2-containing protein suppresses PRL signaling by binding the PRL receptor. Endocrinology. 2001, 142: 5286-5293. 10.1210/en.142.12.5286.View ArticleGoogle Scholar
- Raccurt M, Tam SP, Lau P, Mertani HC, Lambert A, Garcia-Caballero T, Li H, Brown RJ, McGuckin MA, Morel G, Waters MJ: Suppressor of cytokine signalling gene expression is elevated in breast carcinoma. Br J Cancer. 2003, 89: 524-532. 10.1038/sj.bjc.6601115.View ArticleGoogle Scholar
- Sotiropoulos A, Moutoussamy S, Renaudie F, Clauss M, Kayser C, Gouilleux F, Kelly PA, Finidori J: Differential activation of Stat3 and Stat5 by distinct regions of the growth hormone receptor. Mol Endocrinol. 1996, 10: 998-1009. 10.1210/me.10.8.998.Google Scholar
- Herber B, Truss M, Beato M, Muller R: Inducible regulatory elements in the human cyclin D1 promoter. Oncogene. 1994, 9: 2105-2107.Google Scholar
- Brockman JL, Schuler LA: Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter. Mol Cell Endocrinol. 2005, 239: 45-53. 10.1016/j.mce.2005.04.006.View ArticleGoogle Scholar
- Gouilleux F, Wakao H, Mundt M, Groner B: Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. Embo J. 1994, 13: 4361-4369.Google Scholar
- Wyszomierski SL, Rosen JM: Cooperative effects of STAT5 (signal transducer and activator of transcription 5) and C/EBPbeta (CCAAT/enhancer-binding protein-beta) on beta-casein gene transcription are mediated by the glucocorticoid receptor. Mol Endocrinol. 2001, 15: 228-240. 10.1210/me.15.2.228.Google Scholar
- LeBaron MJ, Xie J, Rui H: Evaluation of genome-wide chromatin library of Stat5 binding sites in human breast cancer. Mol Cancer. 2005, 4: 6-10.1186/1476-4598-4-6.View ArticleGoogle Scholar
- Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007, 46: 2398-2410. 10.1021/bi061958v.View ArticleGoogle Scholar
- Kline JB, Roehrs H, Clevenger CV: Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem. 1999, 274: 35461-35468. 10.1074/jbc.274.50.35461.View ArticleGoogle Scholar
- Peirce SK, Chen WY: Quantification of prolactin receptor mRNA in multiple human tissues and cancer cell lines by real time RT-PCR. J Endocrinol. 2001, 171: R1-4. 10.1677/joe.0.171R001.View ArticleGoogle Scholar
- Shiu RP, Murphy LC, Tsuyuki D, Myal Y, Lee-Wing M, Iwasiow B: Biological actions of prolactin in human breast cancer. Recent Prog Horm Res. 1987, 43: 277-303.Google Scholar
- Naylor LH: Reporter gene technology: the future looks bright. Biochem Pharmacol. 1999, 58: 749-757. 10.1016/S0006-2952(99)00096-9.View ArticleGoogle Scholar
- Voon DC, Subrata LS, Baltic S, Leu MP, Whiteway JM, Wong A, Knight SA, Christiansen FT, Daly JM: Use of mRNA- and protein-destabilizing elements to develop a highly responsive reporter system. Nucleic Acids Res. 2005, 33: e27-10.1093/nar/gni030.View ArticleGoogle Scholar
- Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Lazaro-Trueba I, Martin-Perez J: Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol. 2003, 17: 2268-2282. 10.1210/me.2002-0422.View ArticleGoogle Scholar
- Verdier F, Rabionet R, Gouilleux F, Beisenherz-Huss C, Varlet P, Muller O, Mayeux P, Lacombe C, Gisselbrecht S, Chretien S: A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B. Mol Cell Biol. 1998, 18: 5852-5860.View ArticleGoogle Scholar
- Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol. 2004, 22: 2053-2060. 10.1200/JCO.2004.11.046.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.